Concepedia

Lev Demidov

LD

Statistics

Publications

67

Citations

15.4K

H-Index

37

Active since

1992

Affiliations

Russian Cancer Research Center NN Blokhin(Current)

The Maria Sklodowska-Curie National Research Institute of Oncology

University Hospital of Zurich

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Ministry of Health of the Russian Federation

Lev Demidov is an author at Russian Cancer Research Center NN Blokhin specializing in medicine, oncology, and radiation oncology.

ORCID

Top concepts

Publications per year

1992–2023

67

Publications

67

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov et al. · The Lancet · 2012 · 2.9K citations

, , +6

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

James Larkin, Paolo A. Ascierto, Brigitte Dréno et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · Zurich Open Repository and Archive (University of Zurich) · 2012 · 1.3K citations

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Paolo A. Ascierto, Grant A. McArthur, Brigitte Dréno et al. · The Lancet Oncology · 2016 · 986 citations

, , +7

1–5 of 67